NCT02071056View on ClinicalTrials.gov

Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM)

CompletedOBSERVATIONAL
Enrollment

5

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

November 25, 2015

Study Completion Date

November 25, 2015

Conditions
Leptomeningeal Metastasis
Trial Locations (1)

03756

Dartmouth-Hitchcock Medical Center, Lebanon

All Listed Sponsors
lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT02071056 - Circulating Tumor DNA in Cerebrospinal Fluid as an Early Biomarker of Leptomeningeal Metastasis (LM) | Biotech Hunter | Biotech Hunter